Obesity-driven HFpEF: what the drugs do

A systematic review published on 12 August 2026 in Current Problems in Cardiology argues that obesity-driven heart failure with preserved ejection fraction should be managed as a metabolic disease that shows up in the heart, rather than as a pumping problem that happens to occur in people with obesity^[1]. Heart failure with preserved ejection fraction, usually shortened to HFpEF, means the heart squeezes normally but has become stiff enough that it struggles to fill between beats. The result is breathlessness and exercise intolerance in someone whose scan looks reassuring. Plenty of people already taking semaglutide or tirzepatide for weight have exactly those symptoms and have never been told that randomised trials of both drugs have been run in this exact condition.

What obesity does to a stiff heart

Alhazmi and colleagues describe the dominant pathology as visceral and epicardial adiposity, systemic inflammation, impaired myocardial energetics, endothelial dysfunction, and elevation in filling pressures on exertion^[1]. In plainer language, the drivers are fat stored deep in the abdomen and directly on the surface of the heart, a low-grade inflammatory state throughout the body, a heart muscle that handles its fuel badly, blood vessel linings that do not relax as they should, and pressures inside the heart that climb the moment a person starts moving. That last item explains why symptoms turn up on a staircase and not on a sofa.

The review's conclusion follows from that list. It calls obesity-driven HFpEF a cardiometabolic syndrome with heart failure expression, and argues that treatment should target the metabolic drivers rather than only the fluid^[1]. That is the reason a weight-management drug ended up being tested as a heart drug at all. More on the dual GIP and GLP-1 molecule sits on our peptide pages.

What the trials actually moved

STEP-HFpEF randomised 529 patients with HFpEF and obesity to once-weekly semaglutide 2.4 mg or placebo for 52 weeks. The Kansas City Cardiomyopathy Questionnaire clinical summary score, a patient-reported measure of symptom burden and physical limitation, improved by 16.6 points on semaglutide against 8.7 on placebo, a difference of 7.8 points (P<0.001). Body weight fell 13.3% against 2.6%. Six-minute walk distance improved by 21.5 metres against 1.2 metres, and C-reactive protein, a blood marker of inflammation, fell 43.5% against 7.3%^[2].

STEP-HFpEF DM repeated the design in 616 patients who also had type-2 diabetes and found a smaller but consistent effect: 13.7 points against 6.4 on the questionnaire, weight down 9.8% against 3.4%, and 14.3 metres more on the walk test (P=0.008)^[3]. Serious adverse events were less common on the drug in both trials, at 13.3% against 26.7% in STEP-HFpEF and 17.7% against 28.8% in the diabetes trial^[2][3].

SUMMIT is the tirzepatide trial. Its published primary endpoint was a composite of clinical events, where the two semaglutide trials reported symptom score and body weight as their primary outcomes. It randomised 731 patients with an ejection fraction of 50% or higher and a body-mass index of 30 or higher to tirzepatide up to 15 mg weekly by subcutaneous injection or to placebo, with a median 104 weeks of follow-up. The composite of cardiovascular death or worsening heart failure occurred in 9.9% on tirzepatide against 15.3% on placebo (hazard ratio 0.62, 95% CI 0.41 to 0.95, P=0.026), and the questionnaire score rose 19.5 points against 12.7 at 52 weeks^[4].

A June 2026 systematic review and meta-analysis in Diseases of the Month pooled five randomised and observational studies covering 47,710 patients with HFpEF and a body-mass index of 30 or higher, followed for 52 to 146 weeks. It reported a hazard ratio of 0.50 (95% CI 0.42 to 0.60, P<0.001) for cardiovascular mortality and worsening heart-failure events on tirzepatide against standard therapy, and no significant difference against semaglutide (hazard ratio 0.95, P=0.31)^[5].

What these trials did not show

None of the three was a mortality trial, and none should be read as one. In SUMMIT the composite benefit came from worsening heart-failure events (8.0% against 14.2%, hazard ratio 0.54). Cardiovascular deaths ran 2.2% on tirzepatide against 1.4% on placebo, a hazard ratio of 1.58 on very small counts^[4]. Those counts are too few to say anything in either direction, and they are not a survival result. Discontinuation for adverse events was also higher on tirzepatide, at 6.3% against 1.4%, driven mainly by gastrointestinal effects, which is consistent with the tirzepatide safety summary and the semaglutide safety summary on this site^[4].

A proposed framework is not a guideline

The practical output of the review is a sequence: diagnosis, fluid management, SGLT2 inhibition as foundational therapy, obesity-directed therapy, then selective additional intensification^[1]. The authors also position finerenone as an option, while flagging that obesity-specific data for it remain indirect^[1].

Read that sequence for what it is. It is a proposal made by four authors inside a review article, and it has not been through a cardiology society guideline committee. A review also cannot change what a medicine is licensed to do. Label status is set by regulators, varies by country and moves, so the reference points are the tirzepatide regulation summary and the semaglutide regulation summary, which we maintain per country.

What we do not yet know

Weight fell substantially in every active arm of every trial here, so the designs cannot separate the benefit of losing weight from any direct effect of these molecules on heart muscle and blood vessels. The review lists impaired myocardial energetics and endothelial dysfunction among the drivers^[1], but it does not establish which of those the drugs actually corrected. Our note on the open questions for tirzepatide covers the same gap from the drug side.

Duration is the second gap. The semaglutide trials ran 52 weeks and SUMMIT ran a median of 104 weeks, so nothing published here speaks to a decade of continuous treatment or to what happens if someone stops^[2][4]. No randomised trial has compared the two drugs head to head in this population either. The only comparison on record is the indirect one inside that pooled analysis, and it found no significant difference^[5]. How quickly protection appears is a separate question, covered in our piece on time to benefit for incretin therapies in HFpEF.

Taking this to a clinician

If you are taking a GLP-1 or dual-agonist medicine for weight and you are getting breathless on stairs, or cannot manage exercise you used to manage comfortably, raise it with a doctor rather than matching yourself to a trial abstract. Diagnosis is the first step in the review's own sequence for a reason^[1]. Nothing here is a reason to start, stop or change a prescription medicine, and none of it is medical advice. Those decisions belong with a clinician who can see your history and your test results. The semaglutide overview and the tirzepatide overview set out what each drug is licensed to do.